Evelo Biosciences Shares Drop 12% After Public Offering Prices
Evelo Biosciences Shares Drop 12% After Public Offering Prices
DJ Evelo Biosciences Shares Drop 12% After Public Offering Prices
By Chris Wack
Evelo Biosciences Inc. shares were down 12% to $16.33 Friday after the company priced an underwritten public offering of 4.5 million common shares at $15 a share.
Evelo granted the underwriters a 30-day option, solely to cover any over-allotments, to purchase up to an additional 675,000 shares of its common stock.
The proceeds from the offering are expected to be $67.5 million, the company said. All of the shares in the offering are to be sold by Evelo.
The offering is expected to close on or about Tuesday.
Evelo said it intends to use the proceeds from the offering, in addition to its existing cash resources, to continue the development of EDP1815 in a Phase 2 trial in psoriasis and initiate a Phase 2 trial of EDP1815 in atopic dermatitis; prepare to advance EDP1815 in multiple Phase 3 trials in psoriasis and atopic dermatitis, upon receipt of positive Phase 2 data; continue the Phase 2 and Phase 2/3 clinical trials of EDP1815 for the treatment of hyperinflammation caused by SARs-CoV-2; and for working capital and other general corporate purposes.
The stock hit a 52-week high of $19.93 on Thursday.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 29, 2021 10:03 ET (15:03 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Evelo Biosciences Shares Drop 12% After Public Offering Prices
DJ Evelo Biosciences股价在公开募股价格后下跌12%
By Chris Wack
克里斯·瓦克(Chris Wack)著
Evelo Biosciences Inc. shares were down 12% to $16.33 Friday after the company priced an underwritten public offering of 4.5 million common shares at $15 a share.
Evelo Biosciences Inc.股价上周五下跌12%，至16.33美元，此前该公司将450万股普通股的承销公开发行定价为每股15美元。
Evelo granted the underwriters a 30-day option, solely to cover any over-allotments, to purchase up to an additional 675,000 shares of its common stock.
Evelo授予承销商30天的选择权，仅用于支付任何超额配售，以额外购买至多67.5万股普通股。
The proceeds from the offering are expected to be $67.5 million, the company said. All of the shares in the offering are to be sold by Evelo.
该公司表示，此次发行的收益预计为6750万美元。此次发行的所有股票都将由Evelo出售。
The offering is expected to close on or about Tuesday.
预计此次发行将于周二左右结束。
Evelo said it intends to use the proceeds from the offering, in addition to its existing cash resources, to continue the development of EDP1815 in a Phase 2 trial in psoriasis and initiate a Phase 2 trial of EDP1815 in atopic dermatitis; prepare to advance EDP1815 in multiple Phase 3 trials in psoriasis and atopic dermatitis, upon receipt of positive Phase 2 data; continue the Phase 2 and Phase 2/3 clinical trials of EDP1815 for the treatment of hyperinflammation caused by SARs-CoV-2; and for working capital and other general corporate purposes.
Evelo公司说，除了现有的现金资源外，它还打算利用发行所得资金继续开发EDP1815，进行牛皮癣的第二阶段试验，并启动EDP1815治疗特应性皮炎的第二阶段试验；准备在收到阳性的第二阶段数据后，推进EDP1815在牛皮癣和特应性皮炎的多个第三阶段试验；继续EDP1815治疗SARS-CoV-2引起的过敏性炎症的第二阶段和第二/3阶段临床试验；
The stock hit a 52-week high of $19.93 on Thursday.
该股周四触及52周高点19.93美元。
Write to Chris Wack at chris.wack@wsj.com
写信给克里斯·瓦克(chris.wack@wsj.com)
(END) Dow Jones Newswires
(完)道琼通讯社
January 29, 2021 10:03 ET (15:03 GMT)
2021年1月29日美国东部时间10：03(格林尼治标准时间15：03)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧